Business
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Please check out the biopharma industry’s COVID-19 stories that are trending for May 4, 2021.
Clinical-stage precision medicine company Relay Therapeutics has brought two new senior level management team members into the fold, including Tara O’Meara and Charles Ferté.
One year after Astellas and California-based Cytokinetics extended an agreement to develop Skeletal Sarcomere Activators, the Japanese pharma company is walking away from the deal.
Grabbing a fast-tracked novel enzyme replacement therapy for a rare pediatric disease, new biopharma Aceragen launched with $35 million in hand for product financing.
As Tenaerts takes the scientific helm at Medable, she will leverage the company’s proprietary platform to advance decentralized research methodologies with evidence-based best practices for patient-centric clinical trials.
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
Battered by vaccine manufacturing mishaps that led to the contamination of 15 million doses of the Johnson & Johnson vaccine, Emergent BioSolutions is shaking up its leadership to ensure such errors do not occur again.
Work-at-home arrangements created to respond to the COVID-19 pandemic have forced numerous companies in most sectors to reevaluate their work deals. This has also resulted in rethinking site locations and real estate needs. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.